Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18793899 | 0.87 | MAPK1 (0.46) | MAPK1ACACBGPR88XIAPBIRC2 | |
| SCHEMBL29675377 | 0.84 | ACACB (0.46) | MAPK1ACACBSMN1; SMN2KMT2A | |
| SCHEMBL23343856 | 0.82 | MAPK1 (0.40) | MAPK1ACACBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29676873 | 0.81 | MAPK1 (0.39) | MAPK1ACACBSMN1; SMN2 | |
| SCHEMBL29676835 | 0.78 | MAPK1 (0.38) | MAPK1ACACBSMN1; SMN2 | |
| SCHEMBL20738589 | 0.74 | NCF1 (0.34) | ACACB | |
| SCHEMBL24925820 | 0.74 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL29676186 | 0.71 | ACACB (0.48) | MAPK1ACACB | |
| SCHEMBL29675736 | 0.70 | ACACB (0.40) | MAPK1ACACBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29918423 | 0.69 | MAPK1 (0.57) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MAPK1 1/4885ACACB 3916/4885SMN1; SMN2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.